Alkermes (ALKS) recently announced encouraging top-line data from a phase II study (n=142) on ALKS 5461. The study evaluated the safety and efficacy of ALKS 5461 across two doses for the treatment of major depressive disorder (MDD)...

We have crossed the halfway mark in the Q1 earnings season, with results from 271 S&P 500 companies already out (as of Friday, April 26th). Please note that these 271 companies are more than just 54.2% of the index’s total membership –...

2May2013 | vitalstocks | Comments Off on (PFE) Grading the First Quarter Earnings Season – Earnings Preview | Continued

Mallinckrodt, the Pharmaceuticals business of Covidien plc (COV), launched more dosages of the Concerta (methylphenidate HCl) Extended-Release (ER) Tablets USP (CII). The company introduced the new 36 mg and 54 mg dosage strengths.

The pharmaceutical industry has been showing signs of recovery from one of the biggest patent cliffs in recent times. The last few quarters saw major blockbusters like Merck’s (MRK) Singulair, Pfizer’s (PFE)...

AstraZeneca (AZN) recently announced that it plans to initiate strategic reforms in its research and development (R&D) segment. As per proposed plans, the company’s R&D activities will be primarily centered in three facilities...

1Apr2013 | vitalstocks | Comments Off on (AZN) AstraZeneca to Revamp Research and Development Structure | Continued

We are in the midst of the fourth quarter earnings season and it is once again time to review the players in the worldwide medical devices market. The US still holds the leading position with almost one-third of the market share. However, emerging economies like Brazil, Russia, India and China –...

Mallinckrodt, the Pharmaceuticals business of Covidien plc (COV), has won the U.S. Food and Drug Administration (FDA) approval to manufacture and sell a generic version of CONCERTA (methylphenidate HCl) Extended-Release (ER) Tablets...

Merck (MRK) is collaborating with GE Healthcare for the use of an investigational positron emission tomography (PET) imaging agent [18F (flutemetamol)] in the development of Merck’s Alzheimer’s disease candidate, MK-8931.

Actelion (ALIOF) recently announced positive results from a phase II study on its S1P1 modulator, ponesimod. Actelion is evaluating ponesimod as a treatment for patients suffering from moderate-to-severe chronic plaque psoriasis.

AstraZeneca (AZN) recently received some positive news when the Court of Appeals for the Federal Circuit maintained an earlier ruling that the US substance patent (RE37, 314) related to Crestor (rosuvastatin calcium) is valid. The...

The pharmaceutical industry is slowly showing signs of recovery from one of the biggest patent cliffs in recent times. The last few quarters saw major blockbusters like Merck’s (MRK) Singulair, Pfizer’s...

Strong September retail sales data coupled with better-than-expected quarterly results by Citigroup drove the benchmarks into the positive territory yesterday. The positive tone helped benchmarks to rebound from its previous week’s losses and guided Dow to register its biggest gain in one month....

Switzerland-based pharmaceutical company, Novartis AG (NVS) recently announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) gave a positive opinion on Votubia (everolimus) for...

9Oct2012 | vitalstocks | Comments Off on (NVS) Novartis’ Votubia Earns Positive Comments from Committee for Medicinal Products for Human Use | Continued

Eli Lilly and Company’s (LLY) Cialis (tadalafil) recently received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). The CHMP issued an opinion in favor of approving...

9Oct2012 | vitalstocks | Comments Off on (LLY) Eli Lilly and Company’s Cialis Gets Opinion From Committee for Medicinal Products for Human Use | Continued

The HealthCare unit of Bayer (BAYRY) recently announced that the US Food and Drug Administration (FDA) has cleared its oncology candidate, Stivarga (regorafenib). The FDA approved Stivarga, an oral multi-kinase inhibitor, for use...